Regenxbio Inc. (NASDAQ:RGNX)’s share price rose 2.3% on Thursday . The stock traded as high as $7.87 and last traded at $7.70, with a volume of 70,869 shares. The stock had previously closed at $7.53.

RGNX has been the topic of several recent research reports. Morgan Stanley increased their price objective on shares of Regenxbio from $34.00 to $36.00 in a research note on Friday, April 8th. Chardan Capital reiterated a “buy” rating on shares of Regenxbio in a research note on Tuesday, May 10th. Zacks Investment Research upgraded shares of Regenxbio from a “hold” rating to a “buy” rating and set a $8.75 price objective on the stock in a research note on Wednesday, July 6th. Finally, Piper Jaffray Cos. reiterated a “buy” rating and issued a $33.00 price objective on shares of Regenxbio in a research note on Tuesday, July 5th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $28.35.

The stock has a 50 day moving average of $9.23 and a 200-day moving average of $11.45. The stock’s market capitalization is $208.60 million.

Regenxbio (NASDAQ:RGNX) last posted its earnings results on Thursday, May 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by $0.01. On average, equities research analysts predict that Regenxbio Inc. will post ($2.37) earnings per share for the current fiscal year.

In other Regenxbio news, insider Fmr Llc sold 18,300 shares of Regenxbio stock in a transaction dated Tuesday, May 17th. The stock was sold at an average price of $12.41, for a total value of $227,103.00. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

REGENXBIO Inc is a biotechnology company. The Company is focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. Its AAV gene delivery platform (its NAV Technology Platform) consists of rights to over 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10 (NAV Vectors).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.